# Belinostat

Source: https://onco.cc/drugs/belinostat/  
OnCo record `belinostat` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Belinostat is an HDAC inhibitor for relapsed peripheral T-cell lymphoma; about a quarter of patients respond, and it can be used in patients with low platelets.

## Summary

Belinostat is a hydroxamate pan-HDAC inhibitor that blocks class I, II and IV histone deacetylases, increasing acetylation of histones and non-histone proteins with antiproliferative effects in T-cell lymphoma. It is used intravenously in relapsed or refractory peripheral T-cell lymphoma and can be given to patients with low platelet counts, which sets it apart from some alternatives. The BELIEF study (2014) reported a 26% response rate with a median response duration of 10.8 months, supporting accelerated US approval in 2014. The dose is reduced in patients homozygous for UGT1A1*28 because they clear the drug more slowly, and combination with CHOP (Bel-CHOP) has been studied in the front line. Randomised survival evidence is lacking, as for other single-agent PTCL approvals. In short, belinostat helps about a quarter of relapsed PTCL patients and is tolerable when blood counts are poor.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Tags: gap-fill
- Brand: Beleodaq
- Modality: Pan-HDAC inhibitor (hydroxamate)
- Mechanism: Inhibits class I, II and IV histone deacetylases, increasing acetylation of histone and non-histone proteins with antiproliferative effects in T-cell lymphoma.
- Approvals: US 2014: Relapsed/refractory peripheral T-cell lymphoma

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Belinostat
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=belinostat

## Connected records

- cancers: [Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)](https://onco.cc/cancers/angioimmunoblastic-t-cell-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/)
- companies: [Acrotech Biopharma](https://onco.cc/companies/acrotech-biopharma/), [Spectrum Pharmaceuticals](https://onco.cc/companies/spectrum-pharmaceuticals/)
- trials: [Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL](https://onco.cc/trials/nct04747236/), [To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL](https://onco.cc/trials/nct06072131/)
- terms: [What the NHS in England funds for lymphoma, appraisal by appraisal](https://onco.cc/terms/lymphoma-tx-uk-access/)
- targets: [Histone deacetylases (HDAC)](https://onco.cc/targets/hdac/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/belinostat.json